FOR IMMEDIATE RELEASE

Catabasis Pharmaceuticals to Present the Design of MoveDMD, a Phase 1/2 Trial for its Product Candidate CAT-1004 for the Treatment of Duchenne Muscular Dystrophy, at Parent Project Muscular Dystrophy's Annual Connect Conference

CAMBRIDGE, MA, June 12, 2015 – Catabasis Pharmaceuticals, Inc., a clinical-stage drug development company built on a pathway pharmacology technology platform, today announced that CAT-1004 will be featured in an oral presentation and a poster presentation at the upcoming Parent Project Muscular Dystrophy's (PPMD) Annual Connect Conference. The 2015 PPMD Annual Connect Conference will be held June 18-21, 2015, in Washington, DC, at the Washington Marriott Wardman Park Hotel.

- Joanne Donovan, M.D., Ph.D., chief medical officer of Catabasis, will give a presentation titled "CAT-1004, an Oral Agent Targeting NF-kB in Development for Treatment of Duchenne Muscular Dystrophy: Design of MoveDMD, a Phase 1/2 Trial"
    - The oral presentation will take place during the "We See Strength in Progress" session on Friday, June 19, 2015, at 5pm ET
    - The poster presentation will take place during the Poster Fair on Thursday, June 18, 2015, from 6:30pm-9pm ET in Exhibit Hall C

About CAT-1004

CAT-1004 is an oral small-molecule that inhibits activated NF-kB, a protein that coordinates cellular response to muscular damage, stress and inflammation and plays an important role in muscle health. In skeletal muscle, activated NF-kB drives muscle degeneration and suppresses muscle regeneration. In animal models of DMD, CAT-1004 inhibited activated NF-kB, reduced muscle inflammation and degeneration and increased muscle regeneration. In Phase 1 clinical trials, CAT-1004 inhibited activated NF-kB and was well tolerated with no observed safety concerns. Catabasis Pharmaceuticals expects to initiate enrollment of a Phase 1/2 clinical trial of CAT-1004 for the treatment of DMD, known as the MoveDMD trial, in June 2015.

About MoveDMD

MoveDMD is a Phase 1/2 clinical trial of CAT-1004 in boys ages 4 to 7 with Duchenne muscular dystrophy (DMD) (any confirmed mutation) that Catabasis expects to start enrolling in June 2015. The MoveDMD trial will be a two-part clinical trial investigating the safety and efficacy of CAT-1004 in DMD. The first part of the MoveDMD trial will include 7 days of treatment with CAT-1004 with the goal of evaluating the safety, tolerability and pharmacokinetics of CAT-1004. In addition, the Company will collect data at baseline on the muscles of the lower and upper legs using

magnetic resonance imaging (MRI), physical function (including timed function tests), and muscle strength. The boys in the first part of the trial will be asked to participate, if eligible, in the second part of the trial. The second part of the trial will be planned to evaluate the safety and efficacy of CAT-1004 in DMD over a 12-week period. Additional details of the second part of the trial will be available once the first part is complete and the protocol is finalized.

About Catabasis

Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics using its proprietary Safely Metabolized And Rationally Targeted, or SMART, linker technology platform. The Company's SMART linker technology platform is based on the concept of treating diseases by simultaneously modulating multiple targets in one or more related disease pathways. The Company engineers bi-functional product candidates that are conjugates of two molecules, or bioactives, each with known pharmacological activity, joined by one of its proprietary SMART linkers. The SMART linker conjugates are designed for enhanced efficacy and improved safety and tolerability. The Company's focus is on treatments for rare diseases. The Company is also developing other product candidates for the treatment of serious lipid disorders. For more information on the Company's technology and pipeline of drug candidates, please visit www.catabasis.com.

###

Corporate and Media Contact
Andrea Matthews
Catabasis Pharmaceuticals, Inc.
T: (617) 349-1971
amatthews@catabasis.com